Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ocumension TherapeuticsOCUTF 53 3-Year EPS without NRI Growth Rate is 31.90% as of Dec. 2025, which is at its 10-year median of 31.90. GuruFocus rates OCUTF with a GF Score™ of 53/100 and a GF Value™ of $2.61 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,164 Biotechnology companies, Ocumension Therapeutics ranks better than 68.56% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 31.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 43.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Ocumension Therapeutics was 57.30% per year. The lowest was -23.90% per year. And the median was 31.90% per year.
Ocumension Therapeutics (OTCPK:OCUTF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Ocumension Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
OCUTF vs VRTX, REGN, RVMD: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Ocumension Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocumension Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ocumension Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Ocumension Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 31.90% mean?
Ocumension Therapeutics (OCUTF) has a 3-Year EPS without NRI Growth Rate of 31.90% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ocumension Therapeutics and its competitors. This is near median its historical median of 31.90. According to the industry distribution chart, Ocumension Therapeutics ranks #366 out of 1164 companies in the Biotechnology industry, placing it in the top 31.4%.
Is Ocumension Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Ocumension Therapeutics' current 3-Year EPS without NRI Growth Rate of 31.90% is near median its 10-year median of 31.90. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Ocumension Therapeutics' value of 31.90% is 96.9% above this industry median. Based on the distribution chart, Ocumension Therapeutics ranks #366 out of 1164 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ocumension Therapeutics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ocumension Therapeutics ranks #366 out of 1164 companies for 3-Year EPS without NRI Growth Rate. This puts Ocumension Therapeutics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Ocumension Therapeutics' value of 31.90% is 96.9% above this benchmark. While the company's 10-year median is 31.90 vs. the industry median of 16.20, Ocumension Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,164 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocumension Therapeutics's current 3-Year EPS without NRI Growth Rate of 31.90% is 96.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ocumension Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocumension Therapeutics's current 3-Year EPS without NRI Growth Rate is 31.90%, which is near median its own 10-year median of 31.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (OCUTF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.61, compared to a current price of $0.70 — trading 73.2% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 31.90%, which is near median its 10-year median of 31.90 and 96.9% above the Biotechnology industry median of 16.20. Ocumension Therapeutics' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Ocumension Therapeutics (OCUTF), the current 3-Year EPS without NRI Growth Rate is 31.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocumension Therapeutics (OCUTF) Overvalued in 2026?
Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued.
The current stock price of $0.70 is trading 73.2% below its estimated GF Value™ of $2.61.
GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.
Key valuation signals for OCUTF:
3-Year EPS without NRI Growth Rate: 31.90% (near median its 10-year median of 31.90)
GF Value™: $2.61 vs. price of $0.70 (73.2% below fair value)
Industry Position: 96.9% above the Biotechnology median (#366 of 1164)
No single metric tells the full story. See the OCUTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
53GF Score
Get the complete analysis for OCUTF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCUTF has been successfully added to your 
